The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...

Daiichi Sankyo (TSE: 4568) and AstraZeneca (NASDAQ:AZN) said on Friday that Enhertu received European Union approval for the ...

Breast cancer drug Enhurtu costs about £8,000 each session and is only available privately in England, but it is offered on ...

In Europe, approximately 531,000 breast cancer patients are diagnosed annually, with around 141,000 deaths, and around half of all cases would fall under the HER2-low classification, split between ...

HER2-negative breast cancers are HER2-low and potentially an additional 25% may be HER2-ultra-low. There are no targeted therapies specifically approved for patients with HER2-ultra-low expression ...

These two general immune response findings, immune response at baseline and increasing immune response over time, were also ...

The EC based its decision on data from the DESTINY-Breast06 trial, which included patients whose tumors had very low levels of HER2 expression.

Learn more about whether Haleon plc or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, ...

Learn more about whether Jazz Pharmaceuticals plc or Zoetis Inc. is a better investment based on AAII's A+ Investor grades, ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...